An in vivo comparison of the capacity of striatal versus extrastriatal brain regions to form dopamine from exogenously administered L-dopa

Journal of Neural Transmission

Volumn 103, Issue 11, 1996, Pages 1287-1294

  Brannan, T ^a   Prikhojan, A ^a   Yahr, M D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral microdialysis; Decarboxylation; Dopamine; L dopa; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; 3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BRAIN ENZYME; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA;

ANIMAL EXPERIMENT; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DECARBOXYLATION; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG METABOLISM; ENZYME ACTIVITY; INNERVATION; MALE; MICRODIALYSIS; NERVE ENDING; NONHUMAN; OCCIPITAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION;

EID: 0029843391     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01271189     Document Type: Article

References (20)

1. Amano H, Goshima Y, Akema N, Ueda H, Kubo T, Misu Y (1989) Effects of acute nicotine on catecholamine turnover in various rat brain regions. J Pharmacobio-Dyn 12: 18-23
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1975) Brain dopamine and syndromes of Parkinson and Huntington. J Neurol Sci 30: 415-455
3. Brannan T, Bhardwaj A, Martínez-Tica J, Weinberger J, Yahr MD (1990) Striatal L-dopa metabolism studied in vivo in rats with nigrostriatal lesions. J Neural Transm [P-D Sect] 2: 15-22
4. Brannan T, Martínez-Tica J, Yahr MD (1991) Effect of dietary protein on striatal dopamine formation following L-dopa administration: an in vivo study. Neuropharmacology 30: 1125-1127
5. Brannan T, Martínez-Tica J, Yahr MD (1991) Effect of long-term L-Dopa administration on striatal extracellular dopamine release. Neurology 41: 596-598
6. Brannan T, Martínez-Tica J, Yahr MD (1992) Changes in body temperature markedly affect striatal dopamine release and metabolism: an in vivo study. J Neural Transm [Gen Sect] 89: 193-196
7. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 28: 547-555
8. Chase TN, Mouradian MM, Engber TM (1993) Motor response complications and the function of striatal efferent systems. Neurology 43 [Suppl 6]: 23-27
9. Dahlström A, Fuxe K (1965) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 62 [Suppl 232]: 1-55
10. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) in Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 38: 1236-1239
11. Fearnley JU, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301
12. Hefti F, Melamed E, Wurtman RJ (1981) The site of dopamine formation in rat striatum after L-Dopa administration. J Pharmacol Exp Ther 217: 189-197
13. Hornykiewicz O (1974) The mechanisms of action of L-Dopa in Parkinson's disease. Life Sci 15: 1249-1259
14. Kaplan GP, Hartmen BY, Cerveling CR (1979) Immunohistochemical demonstration of catechol-o-methyltransferase in mammalian brain. Brain Res 167: 241-250
15. Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195: 453-464
16. Melamed E (1988) Mechanism of action of exogenous L-Dopa. Is it a physiological therapy for Parkinson's disease? In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders. Urban & Schwarzenberg, Baltimore, pp 87-94
17. Melamed E, Hefti F, Liebman J, Schlosberg AJ, Wurtman RJ (1980) Serotonergic neurones are not involved in action of L-Dopa in Parkinson's disease. Nature 283: 772-774
18. 18F]DOPA PET study. In: Battistin L, Scarloto G, Caraceni T, Ruggieri S (eds) Parkinson's disease. Lippincott-Raven, Philadelphia, pp 427-431 (Adv Neurol, vol 69)
19. Poewe W (1993) L-Dopa in Parkinson's disease: new directions for research. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders, 2nd ed. Williams & Wilkins, Baltimore, pp 103-114
20. Yahr MD (1977) Long-term levodopa in Parkinson's disease. Lancet 1: 706-707